Akebia Therapeutics Inc (AKBA)

01:12 AM

Akebia Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo

01:12 AM

12:35 PM

H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo

12:35 PM

11:12 AM

Akebia (AKBA) Q1 2026 Earnings Transcript - AOL.com

11:12 AM

10:51 AM

Akebia Therapeutics, Inc. (NASDAQ:AKBA): Is Breakeven Near? - Moomoo

10:51 AM

09:30 AM

Q1 2026 Akebia Therapeutics Inc Earnings Call Transcript - GuruFocus

09:30 AM

08:47 AM

AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan

08:47 AM

05:47 AM

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Zacks Research - MarketBeat

05:47 AM

12:09 PM

Akebia Therapeutics (NASDAQ:AKBA) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat

12:09 PM

May 07, 2026

Akebia Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat

May 07, 2026

May 07, 2026

Akebia plunges 20% on muted Q1 print - MSN

May 07, 2026

May 07, 2026

Akebia Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 07, 2026

May 07, 2026

Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 07, 2026

May 07, 2026

Akebia Therapeutics Q1 Earnings Call Highlights - MarketBeat

May 07, 2026

May 07, 2026

Akebia Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 07, 2026

May 07, 2026

Earnings call transcript: Akebia’s Q1 2026 results miss forecasts, stock drops - Investing.com Canada

May 07, 2026

May 07, 2026

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance UK

May 07, 2026

May 07, 2026

Akebia Therapeutics (NASDAQ: AKBA) swings to Q1 2026 loss amid new Auryxia generic - Stock Titan

May 07, 2026

May 07, 2026

Akebia Therapeutics: Q1 Earnings Snapshot - KVUE

May 07, 2026

May 07, 2026

Akebia (NASDAQ: AKBA) Q1 2026 loss amid Auryxia decline, Vafseo growth - Stock Titan

May 07, 2026

May 07, 2026

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights - Yahoo Finance

May 07, 2026

May 06, 2026

Akebia Q1 2026 earnings preview - MSN

May 06, 2026

May 06, 2026

MSN Money - MSN

May 06, 2026

May 06, 2026

Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

May 06, 2026

May 04, 2026

Akebia gives 7 new hires stock options tied to 208,800 shares - Stock Titan

May 04, 2026

May 04, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 04, 2026

May 04, 2026

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology - 富途牛牛

May 04, 2026

May 01, 2026

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights - Moomoo

May 01, 2026

May 01, 2026

Akebia Therapeutics (NASDAQ:AKBA) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat

May 01, 2026

May 01, 2026

AKBA Forecast, Price Target & Analyst Ratings | AKEBIA THERAPEUTICS INC (NASDAQ:AKBA) - ChartMill

May 01, 2026

May 01, 2026

Earnings Preview: AKBA to Report Financial Results Pre-market on May 07 - Moomoo

May 01, 2026

Apr 30, 2026

Are options traders betting on a big move in Akebia Therapeutics stock? - MSN

Apr 30, 2026

Apr 28, 2026

Akebia (NASDAQ: AKBA) plans major increase in authorized common shares - Stock Titan

Apr 28, 2026

Apr 28, 2026

Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock? - Yahoo Finance

Apr 28, 2026

Apr 24, 2026

Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics - Yahoo Finance

Apr 24, 2026

Apr 23, 2026

Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat

Apr 23, 2026

Apr 23, 2026

Akebia (AKBA) Road Ahead | Q4 2025: EPS Misses ViewsCertified Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Apr 20, 2026

Akebia (AKBA) Stock: Long-Term Outlook Review (Steady Climb) 2026-04-20Verified Analyst Reports - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 20, 2026

Apr 18, 2026

Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023 - GuruFocus

Apr 18, 2026

Apr 18, 2026

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN

Apr 18, 2026

Apr 17, 2026

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Potential Upside of 225.93% Draws Investor Attention - DirectorsTalk Interviews

Apr 17, 2026

Apr 16, 2026

AKBA Should I Buy - Intellectia AI

Apr 16, 2026

Apr 15, 2026

Akebia Therapeutics (NASDAQ: AKBA) asks shareholders to increase authorized stock - Stock Titan

Apr 15, 2026

Apr 15, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 15, 2026

Apr 14, 2026

Leerink reiterates Akebia stock rating on regulatory precedent By Investing.com - Investing.com Australia

Apr 14, 2026

Apr 14, 2026

Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks - Sahm

Apr 14, 2026

Apr 13, 2026

Akebia (AKBA) Initiates Phase 1 Trial for AKB-9090 Targeting Kid - GuruFocus

Apr 13, 2026

Apr 13, 2026

Akebia doses first patients in Phase 1 trial of AKB-9090 - Investing.com Canada

Apr 13, 2026

Apr 13, 2026

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - The Manila Times

Apr 13, 2026